Back to GetFilings.com



Table of Contents

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

     
 X    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended November 30, 2002      File Number 0-288

Robbins & Myers, Inc.

(Exact name of registrant as specified in its charter)
     
Ohio   31-0424220

(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)
     
1400 Kettering Tower, Dayton, Ohio   45423

(Address of Principal executive offices)   (Zip Code)

Registrant’s telephone number including area code (937) 222-2610

None


Former name, former address and former fiscal year if changed since last report

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. YES X NO    

Common shares, without par value, outstanding as of November 30, 2002: 14,350,310

1


TABLE OF CONTENTS

CONSOLIDATED CONDENSED BALANCE SHEET
CONSOLIDATED CONDENSED INCOME STATEMENT
CONSOLIDATED CONDENSED STATEMENT OF CASH FLOWS
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
Part I—Management’s Discussion and Analysis of Financial Condition and Results of Operations
Item 4. Controls And Procedures
Part II—Other Information
Item 6. Exhibits and Reports on Form 8-K
SIGNATURES
CERTIFICATIONS
INDEX TO EXHIBITS
EXHIBIT 99.1 Section 906 Certification of CEO
EXHIBIT 99.2 Section 906 Certification of CFO


Table of Contents

ROBBINS & MYERS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEET
(In thousands)

                       
          November 30,   August 31,
          2002   2002
         
 
          (Unaudited)        
ASSETS
               
Current Assets
               
 
Cash and cash equivalents
  $ 14,161     $ 10,534  
 
Accounts receivable
    107,222       113,711  
 
Inventories:
               
   
Finished products
    30,108       29,000  
   
Work in process
    23,346       22,487  
   
Raw materials
    42,524       40,959  
 
   
     
 
 
    95,978       92,446  
 
Other current assets
    11,684       12,318  
 
Deferred taxes
    14,102       14,071  
 
   
     
 
     
Total Current Assets
    243,147       243,080  
Goodwill
    280,339       271,948  
Other Intangible Assets
    17,529       17,604  
Other Assets
    6,793       6,201  
Property, Plant and Equipment
    268,490       261,926  
 
Less accumulated depreciation
    (123,190 )     (118,067 )
 
   
     
 
 
    145,300       143,859  
 
   
     
 
 
  $ 693,108     $ 682,692  
 
   
     
 
LIABILITIES AND SHAREHOLDERS’ EQUITY
               
Current Liabilities
               
 
Accounts payable
  $ 41,274     $ 41,964  
 
Accrued expenses
    77,147       83,871  
 
Current portion of long-term debt
    6,662       4,526  
 
   
     
 
     
Total Current Liabilities
    125,083       130,631  
Long-Term Debt-Less Current Portion
    214,092       203,920  
Deferred Taxes
    8,905       8,708  
Other Long-Term Liabilities
    72,562       70,863  
Minority Interest
    8,173       8,347  
Shareholders’ Equity
               
 
Common stock
    103,925       103,923  
 
Retained earnings
    177,830       176,627  
 
Accumulated other comprehensive loss
    (17,462 )     (20,057 )
 
   
     
 
 
    264,293       260,493  
 
   
     
 
 
  $ 693,108     $ 682,692  
 
   
     
 

See Notes to Consolidated Condensed Financial Statements

2


Table of Contents

ROBBINS & MYERS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED INCOME STATEMENT
(In thousands, except per share data)
(Unaudited)

                   
      Three Months Ended
      November 30,
     
      2002   2001
     
 
Net sales
  $ 124,828     $ 139,387  
Cost of sales
    83,280       92,443  
 
   
     
 
Gross profit
    41,548       46,944  
SG&A expenses
    33,966       33,761  
Amortization expense
    539       558  
 
   
     
 
Income before interest and income taxes
    7,043       12,625  
Interest expense
    3,858       4,053  
 
   
     
 
Income before income taxes and minority interest
    3,185       8,572  
Income tax expense
    1,067       2,872  
Minority interest
    128       259  
 
   
     
 
Net income
  $ 1,990     $ 5,441  
 
   
     
 
Net income per share:
               
 
Basic
  $ 0.14     $ 0.46  
 
   
     
 
 
Diluted
  $ 0.14     $ 0.43  
 
   
     
 
Dividends per share:
               
 
Declared
  $ 0.055     $ 0.055  
 
   
     
 
 
Paid
  $ 0.055     $ 0.055  
 
   
     
 

See Notes to Consolidated Condensed Financial Statements

3


Table of Contents

ROBBINS & MYERS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENT OF CASH FLOWS
(In thousands)
(Unaudited)

                       
          Three Months Ended
          November 30,
         
          2002   2001
         
 
Operating Activities:
               
 
Net income
  $ 1,990     $ 5,441  
 
Adjustments to reconcile net income to net cash and cash equivalents provided by operating activities:
               
   
Depreciation
    5,049       5,390  
   
Amortization
    539       558  
   
Performance stock awards
    0       63  
   
Changes in operating assets and liabilities:
               
     
Accounts receivable
    7,978       915  
     
Inventories
    (2,292 )     (1,752 )
     
Accounts payable
    (1,096 )     1,631  
     
Accrued expenses
    (5,925 )     (6,348 )
     
Other
    1,127       (2,700 )
 
   
     
 
Net Cash and Cash Equivalents Provided by Operating Activities
    7,370       3,198  
 
Investing Activities:
               
 
Capital expenditures, net of nominal disposals
    (2,913 )     (2,802 )
 
Purchase of Tarby
    (11,926 )     0  
 
Romaco acquisition costs
    0       (2,596 )
 
   
     
 
Net Cash and Cash Equivalents Used by Investing Activities
    (14,839 )     (5,398 )
 
Financing Activities:
               
 
Proceeds from debt borrowings
    28,099       29,173  
 
Payments of long-term debt
    (16,216 )     (31,787 )
 
Proceeds from sale of common stock
    0       1,436  
 
Dividends paid
    (787 )     (647 )
 
   
     
 
Net Cash and Cash Equivalents Provided (Used) by Financing Activities
    11,096       (1,825 )
 
   
     
 
Increase (Decrease) in Cash and Cash Equivalents
    3,627       (4,025 )
Cash and Cash Equivalents at Beginning of Period
    10,534       16,122  
 
   
     
 
Cash and Cash Equivalents at End of Period
  $ 14,161     $ 12,097  
 
   
     
 

See Notes to Consolidated Condensed Financial Statements

4


Table of Contents

ROBBINS & MYERS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
November 30, 2002
(Unaudited)

NOTE 1 — Preparation of Financial Statements
In the opinion of management, the accompanying unaudited consolidated condensed financial statements of Robbins & Myers, Inc. and subsidiaries (“we,” “our”) contain all adjustments, consisting of normally recurring items, necessary to present fairly our financial condition as of November 30, 2002, and August 31, 2002, and the results of our operations and cash flows for the three month periods ended November 30, 2002 and 2001. All intercompany transactions have been eliminated. Certain amounts in the prior period financial statements have been reclassified to conform to the current year presentation.

NOTE 2 — Acquisition
On November 15, 2002, we purchased the stock of Tarby, Inc. (“Tarby”) for $11,926,000. Tarby is a manufacturer and marketer of progressing cavity pumps and components for the general industrial and municipal wastewater markets with annual sales of approximately $6,000,000.

NOTE 3 — Goodwill and Other Intangible Assets
Changes in the carrying amount of goodwill for the three month period ended November 30, 2002, by operating segment, are as follows:

                                 
    Pharmaceutical   Energy   Industrial        
    Segment   Segment   Segment   Total
   
 
 
 
    (In thousands)
Balance as of September 1, 2002
  $ 161,138     $ 68,098     $ 42,712     $ 271,948  
Goodwill acquired during the period
    0       0       7,866       7,866  
Translation adjustments and other
    636       (43 )     (68 )     525  
 
   
     
     
     
 
Balance as of November 30, 2002
  $ 161,774     $ 68,055     $ 50,510     $ 280,339  
 
   
     
     
     
 

Information regarding our other intangible assets is as follows:

                                                 
    As of November 30, 2002   As of August 31, 2002
   
 
    Carrying   Accumulated           Carrying   Accumulated        
    Amount   Amortization   Net   Amount   Amortization   Net
   
 
 
 
 
 
                    (In thousands)                
Patents and Trademarks
  $ 7,260     $ 1,276     $ 5,984     $ 7,260     $ 1,103     $ 6,157  
Non-compete Agreements
    10,752       7,949       2,803       10,752       7,823       2,929  
Financing Costs
    7,092       3,583       3,509       6,668       3,363       3,305  
Pension Intangible
    4,564       0       4,564       4,564       0       4,564  
Other
    2,078       1,409       669       2,038       1,389       649  
 
   
     
     
     
     
     
 
Total
  $ 31,746     $ 14,217     $ 17,529     $ 31,282     $ 13,678     $ 17,604  
 
   
     
     
     
     
     
 

5


Table of Contents

NOTE 4 — Net Income per Share

                       
          Three Months Ended
          November 30,
         
          2002   2001
         
 
          (In thousands, except per share
          amounts)
Numerator:
               
 
Basic:
               
   
Net income
  $ 1,990     $ 5,441  
   
Effect of dilutive securities:
               
     
Convertible debt interest
    582       582  
 
   
     
 
 
Income attributable to diluted shares
  $ 2,572     $ 6,023  
 
   
     
 
Denominator:
               
 
Basic:
               
   
Weighted average shares
    14,344       11,773  
   
Effect of dilutive securities:
               
     
Convertible debt
    2,191       2,191  
     
Dilutive options and restricted shares
    33       156  
 
   
     
 
 
Diluted shares
    16,568       14,120  
 
   
     
 
Basic net income per share
  $ 0.14     $ 0.46  
 
   
     
 
Diluted net income per share — reported (a)
  $ 0.14     $ 0.43  
 
   
     
 
Diluted net income per share — computed (a)
  $ 0.16     $ 0.43  
 
   
     
 

(a)  For the three month period ended November 30, 2002, the computed diluted net income per share is $0.16. However, diluted net income per share may not exceed basic net income per share. Therefore, the reported diluted net income per share is $0.14.

NOTE 5 — Long-Term Debt

           
      November 30, 2002
     
      (In thousands)
Senior debt:
       
 
Revolving credit loan
  $ 20,997  
 
Senior notes
    100,000  
 
Other
    19,630  
10.00% subordinated notes
    20,436  
6.50% Convertible subordinated notes
    59,691  
 
   
 
Total debt
    220,754  
Less current portion
    6,662  
 
   
 
 
  $ 214,092  
 
   
 

Our Bank Credit Agreement (“Agreement”) provides that we may borrow on a revolving credit basis up to a maximum of $126,123,000. All outstanding amounts under the Agreement are due and payable on January 9, 2005. Interest is variable based upon formulas tied to LIBOR or prime, at our option, and is payable at least quarterly. At November 30, 2002, the weighted average interest rate for all amounts outstanding was 4.07%. Indebtedness under the Agreement is unsecured, except for guarantees by our U.S. subsidiaries, the pledge of the stock of our U.S. subsidiaries and the pledge of the stock of certain non-U.S. subsidiaries.

We have $100,000,000 of Senior Notes (“Senior Notes”) issued in two series. Series A in the principal amount of $70,000,000 has an interest rate of 6.76% and is due May 1, 2008, and Series B in the principal amount of $30,000,000 has an interest rate of 6.84% and is due May 1, 2010. Interest is payable semi-annually on May 1 and November 1.

6


Table of Contents

The above agreements have certain restrictive covenants including limitations on cash dividends, treasury stock purchases and capital expenditures, and minimum requirements for interest coverage and leverage ratios. The amount of cash dividends and treasury stock purchases, other than in relation to stock option exercises, we may incur in each fiscal year is restricted to the greater of $3,500,000 or 50% of our consolidated net income for the immediately preceding fiscal year, plus a portion of any unused amounts from the preceding fiscal year. Under this Agreement and other lines of credit, we could incur additional indebtedness of approximately $25,000,000 based on our covenant position.

Our other debt primarily consists of unsecured non-U.S. bank lines of credit with interest rates ranging from 4.00% to 8.00%.

We have $20,436,000 of 10.00% Subordinated Notes (“Subordinated Notes”) with the former owner of Romaco. The Subordinated Notes are due in 2006 and 2007 and interest is payable quarterly.

We have $59,691,000 of 6.50% Convertible Subordinated Notes Due 2003 (“Convertible Subordinated Notes”). The Convertible Subordinated Notes are due on September 1, 2003, and bear interest at 6.50%, payable semi-annually on March 1 and September 1 and are convertible into common stock at a rate of $27.25 per share. Holders may convert at any time until maturity and we may call for redemption at any time until maturity at par.

Subsequent to November 30, 2002, we made an offer to the current holders of the Convertible Subordinated Notes to exchange up to $40,000,000 of the Convertible Subordinated Notes for new Convertible Subordinated Notes that bear interest at 8.00%, are due on January 31, 2008, and are convertible into common stock at a rate of $22.50 per share.

The Convertible Subordinated Notes and the Subordinated Notes are subordinated to all of our other indebtedness.

We have entered into an interest rate swap agreement. The interest rate swap agreement utilized by us effectively modifies our exposure to interest rate risk by converting our fixed rate debt to floating rate debt. This agreement involves the receipt of fixed rate amounts in exchange for floating rate interest payments over the life of the agreement without an exchange of underlying principal amounts. The fair value hedge qualifies for treatment under the short cut method of measuring effectiveness. As a result, there is no impact on earnings due to hedge ineffectiveness. The interest rate swap agreement totals $30,000,000, expires in 2008 and allows us to receive an interest rate of 6.76% and pay an interest rate based on LIBOR.

NOTE 6 — Income Taxes
The estimated annual effective tax rate was 33.5% for the three month periods ended November 30, 2002 and 2001.

7


Table of Contents

NOTE 7 — Comprehensive Income

                   
      Three Months Ended
      November 30,
     
      2002   2001
     
 
      (In thousands)
Net income
  $ 1,990     $ 5,441  
Other comprehensive income:
               
 
Foreign currency translation
    2,610       (2,246 )
 
   
     
 
Comprehensive income
  $ 4,600     $ 3,195  
 
   
     
 

NOTE 8 — Business Segments
Sales and Income before Interest and Taxes (“EBIT”) by operating segment is presented in the following table.

                   
      Three Months Ended
      November 30,
     
      2002   2001
     
 
      (In thousands)
Unaffiliated customer sales:
               
 
Pharmaceutical
  $ 74,946     $ 83,205  
 
Industrial
    27,843       32,443  
 
Energy
    22,039       23,739  
 
   
     
 
 
Total
  $ 124,828     $ 139,387  
 
   
     
 
EBIT:
               
 
Pharmaceutical
  $ 3,722     $ 8,197  
 
Industrial
    1,816       2,270  
 
Energy
    4,513       4,812  
 
Corporate and eliminations
    (3,008 )     (2,654 )
 
   
     
 
 
Total
  $ 7,043     $ 12,625  
 
   
     
 

8


Table of Contents

Part I—Management’s Discussion and Analysis of Financial Condition and Results of Operations

Results of Operations

     The following tables present the components of our consolidated income statement and segment information for the first three month periods of fiscal 2003 and 2002.

                 
    Three Months Ended
    November 30,
   
    2002   2001
   
 
Net sales
    100.0 %     100.0 %
Cost of sales
    66.7       66.3  
 
   
     
 
Gross profit
    33.3       33.7  
SG&A expenses
    27.2       24.2  
Amortization
    0.5       0.4  
 
   
     
 
EBIT
    5.6 %     9.1 %
 
   
     
 
                     
        Three Months Ended
        November 30,
       
        2002   2001
       
 
        (In thousands)
Segment
               
 
Pharmaceutical:
               
   
Sales
  $ 74,946     $ 83,205  
   
EBIT
    3,722       8,197  
   
EBIT%
    5.0 %     9.9 %
 
               
 
Industrial:
               
   
Sales
  $ 27,843     $ 32,443  
   
EBIT
    1,816       2,270  
   
EBIT%
    6.5 %     7.0 %
 
               
 
Energy:
               
   
Sales
  $ 22,039     $ 23,739  
   
EBIT
    4,513       4,812  
   
EBIT%
    20.5 %     20.3 %

Three months ended November 30, 2002

     Net sales for the first quarter of fiscal 2003 were $124.8 million compared with $139.4 million in the first quarter of fiscal 2002.

     The Pharmaceutical segment had sales of $74.9 million in the first quarter of fiscal 2003 compared with $83.2 million in the first quarter of fiscal 2002. The change in exchange rates, primarily the strengthening of the Euro, increased the first quarter of fiscal 2003 sales by $5.1 million compared with the first quarter of fiscal 2002. The sales decline was due to the weak specialty chemical market and slow industrial economy in the U.S. Orders for this segment increased from $74.4 million in the first quarter of fiscal 2002 to $75.0 million in the first quarter of fiscal 2003. Backlog in this segment was $100.7 million at the end of the first quarter of fiscal 2003 compared with $100.8 million at August 31, 2002.

     The Industrial segment had sales of $27.8 million in the first quarter of fiscal 2003 compared with $32.4 million in the first quarter of fiscal 2002. The decline in sales was across all of our businesses in this segment and was again due to the weak specialty chemical market as well as the slow industrial economy in the U.S. Incoming orders in this segment were $30.5 million in the first quarter of fiscal 2003 compared with $27.5 million in the first quarter of fiscal 2002. Backlog in this segment increased to $24.0 million at the end of the first quarter of fiscal 2003 from $21.6 million at August 31, 2002.

9


Table of Contents

     The Energy segment had sales of $22.0 million in the first quarter of fiscal 2003 compared with $23.7 million in the first quarter of fiscal 2002, a decrease of $1.7 million or 7.2%. Crude oil and natural gas drilling activity remain at cyclical lows due to the current inventory levels. Incoming orders in this segment were $22.2 million in the first quarter of fiscal 2003, compared with $21.9 million in the first quarter of fiscal 2002. Backlog increased to $3.5 million at the end of the first quarter of fiscal 2003 from $3.3 million at August 31, 2002.

     EBIT for the first quarter of fiscal 2003 was $7.0 million compared with $12.6 million in the first quarter of fiscal 2002.

     The Pharmaceutical segment had EBIT of $3.7 million in the first quarter of fiscal 2003 compared with $8.2 million in the first quarter of fiscal 2002. The decrease in EBIT was due to lower sales volumes and lower prices in our Reactor Systems’ European operations.

     The Industrial segment had EBIT of $1.8 million in the first quarter of fiscal 2003 compared with $2.3 million in the first quarter of fiscal 2002, a reduction of $0.5 million. We have reduced our operating expenses in this segment and therefore the reduction in EBIT is only $0.5 million on a sales decline of $4.6 million.

     The Energy segment had EBIT of $4.5 million in the first quarter of fiscal 2003 compared with $4.8 million in the first quarter of fiscal 2002, a decrease of $0.3 million or 6.3%. The aforementioned decline in Energy segment sales caused the reduction in EBIT.

     Interest expense decreased from $4.1 million in the first quarter of fiscal 2002 to $3.9 million in the first quarter of fiscal 2003. This was due primarily to lower average debt levels.

     The effective tax rate was 33.5% in fiscal 2003 and fiscal 2002.

     The overall decline in net income and diluted net income per share in the first quarter of fiscal 2003 was due to lower EBIT as a result of lower sales volumes.

10


Table of Contents

Liquidity and Capital Resources

     Cash uses in the first three months of fiscal 2003 were $5.1 million in semi-annual interest payments due on our Senior Notes and Convertible Subordinated Notes, $0.5 million for variable pay plans (both included in accrued expenses), $2.9 million for capital expenditures and $11.9 million for the purchase of Tarby. Cash generated from operations and borrowings under our revolving line of credit funded these cash uses.

     Cash uses in the first three months of fiscal 2002 were $5.3 million in semi-annual interest payments due on our Senior Notes and Convertible Subordinated Notes, $2.8 for variable pay plans, $2.0 million in income tax payments (all included in accrued expenses), $2.8 million for capital expenditures, and $2.6 million in acquisition costs related to the Romaco acquisition. Cash generated from operations funded these cash uses.

     We expect operating cash flow to be adequate for the remainder of fiscal year 2003 operating needs, scheduled debt service and shareholder dividend requirements. The major cash requirement for the remainder of fiscal 2003 is planned capital expenditures of approximately $12.0 million. Capital expenditures are related to additional production capacity, cost reductions and replacement items.

     We have $59.7 million of Convertible Subordinated Notes that are due on September 1, 2003 (fiscal year 2004). We have made an offer to the current holders of the Convertible Subordinated Notes to exchange up to $40.0 million of these notes for new convertible subordinated notes. For any Convertible Subordinated Notes not exchanged, we can use capacity under our Bank Credit Agreement to repay these notes, because utilizing borrowings under our Bank Credit Agreement would not create additional debt and therefore not impact our position with regard to debt covenants.

Market Risk

     In its normal operations we have market risk exposure to foreign currency exchange rates and interest rates. During fiscal 2003 there has been no significant change in our exposure to these risks.

Forward-looking Statements

     In addition to historical information, this report contains forward-looking statements identified by use of words such as “expects,” “anticipates,” “estimates,” and similar expressions. These statements reflect our expectations at the time this report was issued. Actual events and results may differ materially from those described in the forward-looking statements. Among the factors that could cause material differences are significant changes in capital expenditures in the specialty chemical and pharmaceutical industries, a major change in oil and natural gas prices, foreign exchange rate fluctuations, continued availability of acceptable acquisition candidates, access to capital and financing and general economic conditions that can affect demand in the process industries. We undertake no obligation to update or revise any forward-looking statement.

11


Table of Contents

Item 4. Controls And Procedures

(a)   Based on a recent evaluation, which was performed within 90 days of the filing of this Quarterly Report on Form 10-Q, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a-14 and 15d-14) are effective in timely alerting them to material information relating to us (including our consolidated subsidiaries) required to be included in periodic reports filed under the Securities Exchange Act.
 
(b)   There have been no significant changes in our internal controls or in other factors that could significantly affect these controls subsequent to November 30, 2002.

12


Table of Contents

Part II—Other Information

Item 6. Exhibits and Reports on Form 8-K

  a)   Exhibits – see INDEX TO EXHIBITS
 
  b)   Reports on Form 8-K. During the quarter ended November 30, 2002, we filed an 8-K on October 2, 2002 to announce an amendment to the terms of our revolving credit agreement.

13


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

             
            ROBBINS & MYERS, INC.
 
DATE:   January 8, 2003

  BY   /s/ Kevin J. Brown

Kevin J. Brown
Vice President and Chief Financial Officer
(Principal Financial Officer)
 
DATE:   January 8, 2003

  BY   /s/ Thomas J. Schockman

Thomas J. Schockman
Corporate Controller
(Principal Accounting Officer)

14


Table of Contents

CERTIFICATIONS

I, Gerald L. Connelly, certify that:

  1.   I have reviewed this quarterly report on Form 10-Q of Robbins & Myers, Inc. (the “Registrant”).
 
  2.   Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstance under such statements were made, not misleading with respect to the period covered by this quarterly report;
 
  3.   Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this quarterly report;
 
  4.   The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the Registrant and have:

         
    a)   designed such disclosure controls and procedures to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
         
    b)   evaluated the effectiveness of the Registrant’s disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the “Evaluation Date”); and
         
    c)   presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

  5.   The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

         
    a)   all significant deficiencies in the design or operation of internal controls which could adversely affect the Registrant’s ability to record, process, summarize and report financial data and have identified for the Registrant’s auditors any material weaknesses in internal controls; and
         
    b)   any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal controls; and

  6.   The Registrant’s other certifying officer and I have indicated in this quarterly report whether there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

           
Date:   January 8, 2003

   
 
        /s/ Gerald L. Connelly

Gerald L. Connelly
President and Chief Executive Officer

15


Table of Contents

CERTIFICATIONS

I, Kevin J. Brown, certify that:

  1.   I have reviewed this quarterly report on Form 10-Q of Robbins & Myers, Inc. (the “Registrant”).
 
  2.   Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstance under such statements were made, not misleading with respect to the period covered by this quarterly report;
 
  3.   Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this quarterly report;
 
  4.   The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the Registrant and have:

         
    a)   designed such disclosure controls and procedures to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
         
    b)   evaluated the effectiveness of the Registrant’s disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the “Evaluation Date”); and
         
    c)   presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

  5.   The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

         
    d)   all significant deficiencies in the design or operation of internal controls which could adversely affect the Registrant’s ability to record, process, summarize and report financial data and have identified for the Registrant’s auditors any material weaknesses in internal controls; and
         
    e)   any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal controls; and

  6.   The Registrant’s other certifying officer and I have indicated in this quarterly report whether there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

           
Date:   January 8, 2003

   
 
        /s/ Kevin J. Brown

Kevin J. Brown
Vice President and
Chief Financial Officer

16


Table of Contents

INDEX TO EXHIBITS

(99)  OTHER EXHIBITS

     
99.1   Certification of Chief Executive Officer of Robbins & Myers, Inc. in accordance with Section 906 of the Sarbanes-Oxley Act of 2002
 
99.2   Certification of Chief Financial Officer of Robbins & Myers, Inc. in accordance with Section 906 of the Sarbanes-Oxley Act of 2002

17